{"id":"suboxone","rwe":[],"tags":[],"trials":[],"_chembl":{"chemblId":"CHEMBL511142","moleculeType":"Small molecule","molecularWeight":"467.65"},"aliases":["Buprenorphine Naloxone","buprenorphine/naloxone","Subjects will be maintained on 50mg naltrexone","Buprenorphine","buprenorphine"],"patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$17.2295/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$6,289","description":"SUBOXONE 12 MG-3 MG SL FILM","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Suboxone","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:33:43.708170+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:33:49.794668+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Suboxone","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:33:50.258227+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Kappa opioid receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:33:51.303000+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL511142/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:33:50.970876+00:00"}},"offLabel":[],"timeline":[],"_dailymed":{"setId":"8a5edcf9-828c-4f97-b671-268ab13a8ecd","title":"SUBOXONE (BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE) FILM, SOLUBLE [INDIVIOR INC.]"},"ecosystem":[],"_scrapedAt":"2026-03-28T00:09:54.505Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:33:52.607005+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07435077","phase":"PHASE4","title":"Examining Analgesic Synergy and Efficacy in Trauma Care","status":"NOT_YET_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2026-05","conditions":"Opioid Use Disorder","enrollment":282},{"nctId":"NCT04677114","phase":"PHASE2","title":"Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections","status":"COMPLETED","sponsor":"Laura Fanucchi","startDate":"2021-03-16","conditions":"Drug Use, Opioid-use Disorder","enrollment":71},{"nctId":"NCT07485335","phase":"PHASE4","title":"A Bundled Intervention - Phase 2","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-09-07","conditions":"Opioid Use Disorder, Opioid Overdose","enrollment":160},{"nctId":"NCT06576843","phase":"PHASE2","title":"INDV-6001 Multiple-Dose Pharmacokinetic Study","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2024-09-17","conditions":"Moderate to Severe Opioid Use Disorder","enrollment":123},{"nctId":"NCT03911466","phase":"","title":"Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study","status":"COMPLETED","sponsor":"T. John Winhusen, PhD","startDate":"2020-07-21","conditions":"Opioid-Related Disorders, Drug Addiction, Pregnancy Related","enrollment":97},{"nctId":"NCT03911739","phase":"","title":"Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study","status":"COMPLETED","sponsor":"T. John Winhusen, PhD","startDate":"2021-06-14","conditions":"Opioid-Related Disorders, Drug Addiction, Pregnancy Related","enrollment":71},{"nctId":"NCT07469501","phase":"PHASE4","title":"Comparing Outpatient Treatment Retention Among Individuals Using Fentanyl Randomized to Low-dose and Direct-to-inject Buprenorphine Initiation","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-06","conditions":"Opioid Use Disorder, Fentanyl","enrollment":50},{"nctId":"NCT06784180","phase":"PHASE4","title":"Intrathecal Hydromorphone vs Intrathecal Morphine to Treat Post Cesarean Pain in Patients With Opioid Use Disorder Taking Buprenorphine","status":"WITHDRAWN","sponsor":"University of North Carolina, Chapel Hill","startDate":"2026-02","conditions":"Opioid Use Disorder","enrollment":""},{"nctId":"NCT06367387","phase":"PHASE4","title":"Pain Self-Management and Patient-Oriented Dosing for Pain and in Retention Opioid Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Erin Winstanley","startDate":"2024-05-28","conditions":"Opioid Use Disorder, Chronic Pain","enrollment":268},{"nctId":"NCT06726200","phase":"EARLY_PHASE1","title":"A Clinical Trial Comparing Buprenorphine Formulations for High Potency Synthetic Opioid Use","status":"RECRUITING","sponsor":"Rachel R. Luba","startDate":"2026-08","conditions":"Opioid Use Disorder","enrollment":60},{"nctId":"NCT07439549","phase":"PHASE4","title":"Symptom-Inhibited Naloxone Induction (SINI) for Buprenorphine Initiation: A Feasibility Trial","status":"NOT_YET_RECRUITING","sponsor":"Pouya Azar","startDate":"2026-02-18","conditions":"Opioid Use Disorder","enrollment":12},{"nctId":"NCT04245423","phase":"NA","title":"The Whole Health Study: Collaborative Care for OUD and Mental Health Conditions","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2020-12-15","conditions":"Opioid-use Disorder, Mental Health Conditions","enrollment":567},{"nctId":"NCT05180669","phase":"NA","title":"Reward-based Technology to Improve OUD Treatment","status":"TERMINATED","sponsor":"Q2i, LLC","startDate":"2022-11-18","conditions":"Opioid Use Disorder","enrollment":41},{"nctId":"NCT03616236","phase":"PHASE3","title":"Buprenorphine for Probationers and Parolees: Bridging the Gap Into Treatment","status":"SUSPENDED","sponsor":"Friends Research Institute, Inc.","startDate":"2022-07-01","conditions":"Opioid Use","enrollment":320},{"nctId":"NCT06306443","phase":"PHASE3","title":"Buprenorphine for Individuals in Jail","status":"RECRUITING","sponsor":"Friends Research Institute, Inc.","startDate":"2025-07-01","conditions":"Opioid Use Disorder","enrollment":240},{"nctId":"NCT05063201","phase":"PHASE2","title":"Cariprazine for Comorbid Cocaine and Opioid Use Disorder","status":"COMPLETED","sponsor":"Kyle Kampman","startDate":"2022-08-05","conditions":"Opioid-use Disorder, Cocaine Use Disorder","enrollment":26},{"nctId":"NCT04771689","phase":"PHASE4","title":"Buprenorphine/Naloxone Micro-Dosing for Postoperative Pain Management in Opioid-Tolerant Patients","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2022-07-01","conditions":"Post-operative Pain","enrollment":""},{"nctId":"NCT07314346","phase":"PHASE1","title":"Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone","status":"NOT_YET_RECRUITING","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-12","conditions":"Healthy Volunteer Study","enrollment":32},{"nctId":"NCT04091009","phase":"PHASE4","title":"Effect of Standard of Care Reduced Dose Versus Full Dose Buprenorphine/Naloxone in the Perioperative Period on Pain Control and Post-Operative Opioid Use Disorder Symptoms","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2019-10","conditions":"Opioid-use Disorder, Opioid Use Disorder, Mild","enrollment":""},{"nctId":"NCT06023459","phase":"PHASE3","title":"Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yih-Ing Hser","startDate":"2024-10-14","conditions":"Opioid-Related Disorders, Substance-Related Disorders, Narcotic-Related Disorders","enrollment":144},{"nctId":"NCT05546515","phase":"PHASE2","title":"Suvorexant for Opioid/Stimulant Co-use","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2022-12-01","conditions":"Opioid Use Disorder, Stimulant Use Disorder","enrollment":20},{"nctId":"NCT04464980","phase":"PHASE2","title":"Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2021-06-08","conditions":"Opioid Use Disorder (OUD)","enrollment":1516},{"nctId":"NCT04464421","phase":"NA","title":"SMART Effectiveness Trial","status":"COMPLETED","sponsor":"Karen Derefinko, PhD","startDate":"2020-08-17","conditions":"Opioid-use Disorder, Opioid Dependence, Treatment Adherence","enrollment":48},{"nctId":"NCT05118204","phase":"PHASE4","title":"Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization","status":"TERMINATED","sponsor":"Montefiore Medical Center","startDate":"2022-09-29","conditions":"Substance Use Disorders, Opioid-use Disorder, Chronic Pain","enrollment":23},{"nctId":"NCT04161066","phase":"PHASE1","title":"Adjunctive Effects of Psilocybin and a Formulation of Buprenorphine","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2021-01-13","conditions":"Opioid Use Disorder","enrollment":10},{"nctId":"NCT04600414","phase":"NA","title":"Collaborating to Heal Addiction and Mental Health in Primary Care","status":"COMPLETED","sponsor":"University of Washington","startDate":"2020-11-16","conditions":"Opioid-use Disorder, Mental Health Disorder","enrollment":254},{"nctId":"NCT04811014","phase":"PHASE4","title":"Young Houston Emergency Opioid Engagement System","status":"RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2021-04-19","conditions":"Opioid-use Disorder, Opioid Dependence, Opioid Overdose","enrollment":250},{"nctId":"NCT03396276","phase":"PHASE4","title":"Houston Emergency Opioid Engagement System","status":"ENROLLING_BY_INVITATION","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2018-04-01","conditions":"Opioid Use Disorder","enrollment":3000},{"nctId":"NCT05450718","phase":"PHASE4","title":"Low-dose Buprenorphine Initiation for Opioid Use Disorder","status":"RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2024-11-11","conditions":"Opioid Use Disorder","enrollment":70},{"nctId":"NCT05944952","phase":"PHASE4","title":"Low-dose Versus a High-dose Sublingual Buprenorphine Induction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Friends Research Institute, Inc.","startDate":"2024-06-20","conditions":"Opioid Use Disorder","enrollment":40},{"nctId":"NCT05976646","phase":"PHASE1, PHASE2","title":"Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2023-09-18","conditions":"Addiction, Opioid Use, Substance Use Disorders","enrollment":18},{"nctId":"NCT05121428","phase":"","title":"Patients' Attitudes Toward and Experiences With Buprenorphine Treatment","status":"SUSPENDED","sponsor":"Cambridge Health Alliance","startDate":"2021-11-20","conditions":"Opioid-use Disorder, Acceptability of Health Care, Opioid-Related Disorders","enrollment":817},{"nctId":"NCT04948307","phase":"NA","title":"OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder","status":"COMPLETED","sponsor":"Orexo AB","startDate":"2021-06-30","conditions":"Opioid-use Disorder","enrollment":437},{"nctId":"NCT03918850","phase":"PHASE3","title":"Medication Treatment for Opioid Use Disorder in Expectant Mothers","status":"COMPLETED","sponsor":"T. John Winhusen, PhD","startDate":"2020-07-21","conditions":"Opioid-Related Disorders, Drug Addiction, Pregnancy Related","enrollment":140},{"nctId":"NCT03773523","phase":"NA","title":"Neuromodulation and Cognitive Training in Opioid Use Disorder","status":"RECRUITING","sponsor":"University of Minnesota","startDate":"2019-08-01","conditions":"Opioid-use Disorder, Opioid Dependence, Opioid Abuse","enrollment":30},{"nctId":"NCT04893525","phase":"PHASE2, PHASE3","title":"Evaluating Buprenorphine/Naloxone Microdosing vs. Standard Dosing in Emergency Departments","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2021-07-23","conditions":"Opioid-use Disorder","enrollment":658},{"nctId":"NCT05790551","phase":"NA","title":"Suboxone Dispenser for OUD","status":"WITHDRAWN","sponsor":"Addinex Technologies, Inc.","startDate":"2024-01-15","conditions":"Opioid Use Disorder, Opioid Withdrawal","enrollment":""},{"nctId":"NCT05872386","phase":"NA","title":"\"Bupe by the Book\": A Tele-Buprenorphine Clinical Trial in Public Libraries With Unstably Housed Persons With Opioid Use Disorder","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Diego","startDate":"2023-06-28","conditions":"Telehealth at the Library, Control Group","enrollment":60},{"nctId":"NCT05011266","phase":"PHASE2, PHASE3","title":"Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder","status":"RECRUITING","sponsor":"New York State Psychiatric Institute","startDate":"2023-04-18","conditions":"Opioid-use Disorder","enrollment":180},{"nctId":"NCT06494904","phase":"PHASE3","title":"Standard Versus High Dose ED-Initiated Buprenorphine Induction","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-12-06","conditions":"Opioid Use Disorder","enrollment":360},{"nctId":"NCT06406400","phase":"PHASE1","title":"Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2024-05-13","conditions":"Opioid Use Disorder","enrollment":15},{"nctId":"NCT03993392","phase":"PHASE4","title":"SUBLOCADE Rapid Initiation Study","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2019-08-29","conditions":"Opioid-use Disorder","enrollment":26},{"nctId":"NCT04080180","phase":"NA","title":"SMART Trial for Buprenorphine-Naloxone Medication Assisted Treatment Adherence","status":"COMPLETED","sponsor":"Karen Derefinko, PhD","startDate":"2022-02-01","conditions":"Opioid-use Disorder","enrollment":332},{"nctId":"NCT05733442","phase":"NA","title":"Counseling for Harm Reduction and Retention in Medication-assisted Treatment - Cherokee Nation","status":"RECRUITING","sponsor":"Washington State University","startDate":"2023-01-17","conditions":"Opioid Use Disorder","enrollment":136},{"nctId":"NCT04447287","phase":"PHASE1","title":"A Study to Assess the Effect of a Single Dose of ASP8062 on the Multiple Dose Safety, Tolerability and Pharmacokinetics of Buprenorphine/Naloxone in Participants With Opioid Use Disorder","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2020-06-29","conditions":"Opioid Use Disorder","enrollment":23},{"nctId":"NCT04818086","phase":"PHASE1, PHASE2","title":"Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2021-05-03","conditions":"Drug Interaction, Analgesics, Opioid Use Disorder","enrollment":18},{"nctId":"NCT04737603","phase":"PHASE2","title":"Feasibility of Pediatric Emergency Department-Initiated Treatment for Adolescents With Opioid Use Disorder","status":"WITHDRAWN","sponsor":"University of California, Davis","startDate":"2025-07-30","conditions":"Opioid-use Disorder","enrollment":""},{"nctId":"NCT05062577","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants With Opioid Use Disorder","status":"WITHDRAWN","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2021-11-08","conditions":"Opioid Use Disorder","enrollment":""},{"nctId":"NCT03718104","phase":"","title":"MOM NEST Study: Maternal Opioid Medication: Naltrexone Efficacy Study","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2018-12-01","conditions":"Opioid-use Disorder, Neonatal Abstinence Syndrome, Pregnancy, High Risk","enrollment":46},{"nctId":"NCT04253782","phase":"NA","title":"SafetyNet Program for Opioid Use Disorder (OUD)","status":"COMPLETED","sponsor":"Yale University","startDate":"2020-07-01","conditions":"Opioid-Use Disorder (OUD)","enrollment":81},{"nctId":"NCT03908437","phase":"PHASE4","title":"Rapid Initiation of Drug Treatment Engagement","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2019-07-15","conditions":"Opioid-use Disorder, Overdose","enrollment":104},{"nctId":"NCT04976855","phase":"PHASE1","title":"Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2022-08-17","conditions":"Healthy Volunteer, Opioid-use Disorder","enrollment":64},{"nctId":"NCT05644587","phase":"PHASE4","title":"Novel Induction to Buprenorphine/Naloxone","status":"TERMINATED","sponsor":"Bicycle Health","startDate":"2023-02-06","conditions":"Opioid Use Disorder, Opioid Use, Opioid Abuse","enrollment":33},{"nctId":"NCT04480554","phase":"PHASE2","title":"Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2023-01-30","conditions":"Opioid-use Disorder, HIV-1-infection, Immune Activation","enrollment":225},{"nctId":"NCT04234191","phase":"PHASE2","title":"Comparing Rapid Micro-Induction and Standard Induction of Buprenorphine/Naloxone for Treatment of Opioid Use Disorder","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2021-08-18","conditions":"Opioid Use Disorder","enrollment":50},{"nctId":"NCT04794790","phase":"EARLY_PHASE1","title":"Buprenorphine Induction for Fentanyl Dependent Opioid Users","status":"WITHDRAWN","sponsor":"Milton S. Hershey Medical Center","startDate":"2022-05-09","conditions":"Opioid Dependence Fentanyl","enrollment":""},{"nctId":"NCT04283500","phase":"PHASE4","title":"Buprenorphine Loading in the Emergency Department","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2020-11-01","conditions":"Opioid-use Disorder","enrollment":15},{"nctId":"NCT03291847","phase":"PHASE2","title":"Maternal Buprenorphine-naloxone Treatment and the Infant","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2018-06-01","conditions":"Maternal Opioid Use Disorder, Opioid Exposed Infant","enrollment":42},{"nctId":"NCT04049799","phase":"","title":"Maternal Opioid Treatment: Human Experimental Research - Data Yield Appropriate Decisions","status":"COMPLETED","sponsor":"University of Vermont","startDate":"2019-08-08","conditions":"Opioid-use Disorder, Opioid Withdrawal, Neonatal Abstinence Syndrome","enrollment":88},{"nctId":"NCT05164549","phase":"PHASE3","title":"Extended-release Pharmacotherapy for Opioid Use Disorder","status":"COMPLETED","sponsor":"King's College London","startDate":"2019-08-06","conditions":"Opiate Substitution Treatment","enrollment":342},{"nctId":"NCT03976258","phase":"","title":"Effect of Heroin Use on Immune Activation and Cardiovascular Risk in HIV","status":"COMPLETED","sponsor":"MetroHealth Medical Center","startDate":"2017-07-14","conditions":"HIV Infection, Opioid-use Disorder, Cardiovascular Diseases","enrollment":190},{"nctId":"NCT03769025","phase":"PHASE1, PHASE2","title":"Remote Observed Dosing of Suboxone to Improve Clinical Practice","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2019-04-01","conditions":"Opioid-use Disorder, Opioid Dependence, Opiate Dependence","enrollment":16},{"nctId":"NCT04716413","phase":"PHASE4","title":"Evaluating the Use of Sublingual Sufentanil in Patients With Suboxone Treatment","status":"TERMINATED","sponsor":"Montefiore Medical Center","startDate":"2021-09-27","conditions":"Acute Pain","enrollment":3},{"nctId":"NCT04521920","phase":"NA","title":"Providing Suboxone and PrEP Using Telemedicine","status":"COMPLETED","sponsor":"Duke University","startDate":"2020-11-09","conditions":"Opioid Use, Opioid-use Disorder, Risk Reduction","enrollment":17},{"nctId":"NCT01843751","phase":"PHASE3","title":"Dane County Drug Court Study for Addicted Offenders","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2013-03","conditions":"Opioid Dependence","enrollment":24},{"nctId":"NCT01082679","phase":"PHASE2, PHASE3","title":"Treatment for Opioid Dependent Offenders","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2009-06","conditions":"Opioid Dependence","enrollment":16},{"nctId":"NCT03026790","phase":"PHASE2","title":"Veterans' Pain Care Organizational Improvement Comparative Effectiveness Study","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2017-10-19","conditions":"Chronic Pain","enrollment":820},{"nctId":"NCT05307458","phase":"","title":"Evaluating the Pharmacokinetics and Patient Outcomes of Buprenorphine Microdosing","status":"UNKNOWN","sponsor":"United Health Services Hospitals, Inc.","startDate":"2022-07-01","conditions":"Opioid Use Disorder, Opioid Withdrawal","enrollment":20},{"nctId":"NCT05108935","phase":"NA","title":"Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSP","status":"COMPLETED","sponsor":"Duke University","startDate":"2022-02-17","conditions":"Opioid Use, Opioid Use Disorder, Risk Reduction","enrollment":17},{"nctId":"NCT04991974","phase":"PHASE2, PHASE3","title":"Opioid Use Disorder Treatment Linkage at Sexual Health Clinics Using Buprenorphine","status":"UNKNOWN","sponsor":"Friends Research Institute, Inc.","startDate":"2021-09-17","conditions":"Opioid-use Disorder","enrollment":360},{"nctId":"NCT00684073","phase":"PHASE4","title":"Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED)","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2007-07","conditions":"Opiate-related Disorders, Opiate Dependence, Drug Abuse","enrollment":60},{"nctId":"NCT04656899","phase":"NA","title":"Mobile Medication Adherence Platform for Buprenorphine-Naloxone During Treatment of Opioid Use Disorder: Phase I Study","status":"COMPLETED","sponsor":"Washington State University","startDate":"2020-12-06","conditions":"Opioid-use Disorder","enrollment":41},{"nctId":"NCT02187198","phase":"PHASE3","title":"Buprenorphine Treatment for Opioid Dependence","status":"COMPLETED","sponsor":"Yale University","startDate":"2015-03","conditions":"Opioid Dependence","enrollment":9},{"nctId":"NCT05179772","phase":"PHASE2","title":"Olanzapine in OUD Patients","status":"WITHDRAWN","sponsor":"University of Pennsylvania","startDate":"2022-07-28","conditions":"Opioid Use Disorder","enrollment":""},{"nctId":"NCT03580902","phase":"PHASE1, PHASE2","title":"CBT4CBT for Office Based Buprenorphine","status":"COMPLETED","sponsor":"CBT4CBT, LLC","startDate":"2019-01-22","conditions":"Opioid-use Disorder","enrollment":51},{"nctId":"NCT03711318","phase":"PHASE3","title":"Buprenorphine Stabilization and Induction Onto Vivitrol for Heroin-dependent Individuals","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2018-11-01","conditions":"Heroin Dependence","enrollment":8},{"nctId":"NCT04464512","phase":"PHASE4","title":"Suboxone User Perioperative Early Referral and Enhanced Recovery After Surgery- Orthopaedic Trauma Surgery Population","status":"WITHDRAWN","sponsor":"West Virginia University","startDate":"2020-01-10","conditions":"Addiction Opiate, Chronic Pain, Fractures, Bone","enrollment":""},{"nctId":"NCT05594121","phase":"PHASE4","title":"Monthly Versus Daily Buprenorphine Formulations for Treatment of Opiate Use Disorder","status":"UNKNOWN","sponsor":"Royal Victoria Hospital, Canada","startDate":"2022-12","conditions":"Moderate to Severe Opioid Use Disorder","enrollment":90},{"nctId":"NCT04139213","phase":"PHASE2, PHASE3","title":"Medication Maintenance Therapy in Community Pharmacy Settings","status":"UNKNOWN","sponsor":"Lifespan","startDate":"2019-07-25","conditions":"Opioid-use Disorder","enrollment":250},{"nctId":"NCT02696096","phase":"PHASE3","title":"Neuroimaging Predictors of Relapse During Treatment for Opiate Dependence","status":"COMPLETED","sponsor":"Butler Hospital","startDate":"2016-08","conditions":"Opioid Addiction","enrollment":21},{"nctId":"NCT03658642","phase":"NA","title":"Clinical Decision Support to Implement ED-initiated Buprenorphine for OUD","status":"COMPLETED","sponsor":"Yale University","startDate":"2019-11-15","conditions":"Clinical Decision Support, Buprenorphine, Opioid-use Disorder","enrollment":5047},{"nctId":"NCT03744663","phase":"PHASE2","title":"Long Acting Buprenorphine Injection Compared to Sublingual Buprenorphine/Naloxone Films","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2022-06","conditions":"Opioid Use","enrollment":""},{"nctId":"NCT00929253","phase":"NA","title":"Efficacy of Computer Delivered Community Reinforcement Approach (CRA) (Bup II)","status":"COMPLETED","sponsor":"Virginia Polytechnic Institute and State University","startDate":"2007-09","conditions":"Opiate Addiction","enrollment":170},{"nctId":"NCT01936857","phase":"PHASE4","title":"Buprenorphine to Improve HIV Care Engagement and Outcomes","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2015-07","conditions":"HIV, Substance Related Disorders","enrollment":281},{"nctId":"NCT05368675","phase":"PHASE4","title":"Medication-assisted Treatment for Injecting Drug Users in Vietnam","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2013-12-18","conditions":"Opioid Use Disorder, HIV Infections","enrollment":448},{"nctId":"NCT03818399","phase":"PHASE3","title":"Virginia Opioid Overdose Treatment InitiatVE","status":"TERMINATED","sponsor":"Virginia Commonwealth University","startDate":"2019-01-04","conditions":"Opioid Use Disorder","enrollment":19},{"nctId":"NCT03492099","phase":"PHASE2","title":"Assessing the Safety of Buprenorphine in People With Sickle Cell Disease","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2018-08-01","conditions":"Sickle Cell Disease","enrollment":47},{"nctId":"NCT03604159","phase":"PHASE4","title":"XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2019-06-24","conditions":"Opioid Dependence","enrollment":52},{"nctId":"NCT04449744","phase":"NA","title":"Evaluating Adaptive Dispenser Initiation Protocols for MySafeRx During Post-detox Buprenorphine Treatment- a Pilot Study","status":"COMPLETED","sponsor":"University of South Florida","startDate":"2020-07-13","conditions":"Opioid-use Disorder","enrollment":19},{"nctId":"NCT01843023","phase":"PHASE4","title":"Extended Release Naltrexone for Opioid-Dependent Youth","status":"COMPLETED","sponsor":"Friends Research Institute, Inc.","startDate":"2013-06","conditions":"Drug Dependence","enrollment":288},{"nctId":"NCT00270257","phase":"PHASE3","title":"Drug Treatment Combined With Drug and Risk Reduction Counseling to Prevent of HIV Infection and Death Among Injection Drug Users","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-05","conditions":"HIV Infections, Opioid-Related Disorders","enrollment":1251},{"nctId":"NCT01402492","phase":"PHASE2, PHASE3","title":"Cocaine Use Reduction With Buprenorphine","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2011-09","conditions":"Cocaine Dependence","enrollment":302},{"nctId":"NCT02778282","phase":"NA","title":"MySafeRx™: An Integrated Mobile Platform for Buprenorphine Adherence","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2017-03-24","conditions":"Opioid Use Disorder","enrollment":27},{"nctId":"NCT00634803","phase":"PHASE1, PHASE2","title":"Clinical Trial of Integrated Treatment for Pain and Opioid Dependence","status":"COMPLETED","sponsor":"Yale University","startDate":"2009-09","conditions":"Opiate Dependence, Chronic Pain","enrollment":90},{"nctId":"NCT03248947","phase":"EARLY_PHASE1","title":"Buprenorphine Physician-Pharmacist Collaboration in the Management of Patients With Opioid Use Disorder: CTN 0075","status":"COMPLETED","sponsor":"Duke University","startDate":"2018-03-28","conditions":"Opioid Use Disorder","enrollment":71},{"nctId":"NCT00539123","phase":"NA","title":"Drug Counseling and Abstinent-Contingent Take-Home Buprenorphine in Malaysia","status":"COMPLETED","sponsor":"Yale University","startDate":"2007-09","conditions":"Opiate Dependence","enrollment":234},{"nctId":"NCT04234516","phase":"PHASE4","title":"Anti-suicidal Effects of Buprenorphine in Opioid Use Disorder","status":"WITHDRAWN","sponsor":"New York State Psychiatric Institute","startDate":"2020-01-20","conditions":"Opioid-use Disorder, Suicidal Ideation","enrollment":""},{"nctId":"NCT03033732","phase":"PHASE4","title":"A Pragmatic Randomized Control Trial Comparing Models of Care in the Management of Prescription Opioid Misuse","status":"COMPLETED","sponsor":"Didier Jutras Aswad","startDate":"2017-10-02","conditions":"Opioid Use Disorder","enrollment":272},{"nctId":"NCT03235154","phase":"PHASE4","title":"A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic","status":"COMPLETED","sponsor":"Community Research Initiative of New England","startDate":"2017-10-11","conditions":"Hepatitis C, Chronic, Hepatitis C, Opiate Dependence","enrollment":11},{"nctId":"NCT04523792","phase":"PHASE3","title":"Virginia Opioid Treatment-Emergency Department","status":"WITHDRAWN","sponsor":"Virginia Commonwealth University","startDate":"2021-01-01","conditions":"Opioid Use Disorder","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":4368,"reaction":"DRUG DEPENDENCE"},{"count":3610,"reaction":"DRUG WITHDRAWAL SYNDROME"},{"count":2647,"reaction":"PAIN"},{"count":2186,"reaction":"OFF LABEL USE"},{"count":1887,"reaction":"OVERDOSE"},{"count":1753,"reaction":"NAUSEA"},{"count":1473,"reaction":"EMOTIONAL DISTRESS"},{"count":1467,"reaction":"VOMITING"},{"count":1429,"reaction":"ANXIETY"},{"count":1255,"reaction":"FOETAL EXPOSURE DURING PREGNANCY"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"chemblId":"CHEMBL511142"},"formularyStatus":[],"_approvalHistory":[{"date":"20161216","type":"SUPPL","sponsor":"INDIVIOR","applicationNumber":"NDA022410"},{"date":"20140428","type":"SUPPL","sponsor":"INDIVIOR","applicationNumber":"NDA022410"},{"date":"20160415","type":"SUPPL","sponsor":"INDIVIOR","applicationNumber":"NDA022410"},{"date":"20140605","type":"SUPPL","sponsor":"INDIVIOR","applicationNumber":"NDA022410"},{"date":"20170919","type":"SUPPL","sponsor":"INDIVIOR","applicationNumber":"NDA022410"},{"date":"20150922","type":"SUPPL","sponsor":"INDIVIOR","applicationNumber":"NDA022410"},{"date":"20140312","type":"SUPPL","sponsor":"INDIVIOR","applicationNumber":"NDA022410"},{"date":"20150922","type":"SUPPL","sponsor":"INDIVIOR","applicationNumber":"NDA022410"},{"date":"20120810","type":"SUPPL","sponsor":"INDIVIOR","applicationNumber":"NDA022410"},{"date":"20140428","type":"SUPPL","sponsor":"INDIVIOR","applicationNumber":"NDA022410"},{"date":"20251222","type":"SUPPL","sponsor":"INDIVIOR","applicationNumber":"NDA022410"},{"date":"20230313","type":"SUPPL","sponsor":"INDIVIOR","applicationNumber":"NDA022410"},{"date":"20250221","type":"SUPPL","sponsor":"INDIVIOR","applicationNumber":"NDA022410"},{"date":"20220617","type":"SUPPL","sponsor":"INDIVIOR","applicationNumber":"NDA022410"},{"date":"20200302","type":"SUPPL","sponsor":"INDIVIOR","applicationNumber":"NDA022410"},{"date":"20220503","type":"SUPPL","sponsor":"INDIVIOR","applicationNumber":"NDA022410"},{"date":"20170919","type":"SUPPL","sponsor":"INDIVIOR","applicationNumber":"NDA022410"},{"date":"20181026","type":"SUPPL","sponsor":"INDIVIOR","applicationNumber":"NDA022410"},{"date":"20161216","type":"SUPPL","sponsor":"INDIVIOR","applicationNumber":"NDA022410"},{"date":"20140812","type":"SUPPL","sponsor":"INDIVIOR","applicationNumber":"NDA022410"},{"date":"20180611","type":"SUPPL","sponsor":"INDIVIOR","applicationNumber":"NDA022410"},{"date":"20160707","type":"SUPPL","sponsor":"INDIVIOR","applicationNumber":"NDA022410"},{"date":"20140428","type":"SUPPL","sponsor":"INDIVIOR","applicationNumber":"NDA022410"},{"date":"20180201","type":"SUPPL","sponsor":"INDIVIOR","applicationNumber":"NDA022410"},{"date":"20170213","type":"SUPPL","sponsor":"INDIVIOR","applicationNumber":"NDA022410"},{"date":"20131122","type":"SUPPL","sponsor":"INDIVIOR","applicationNumber":"NDA022410"},{"date":"20150623","type":"SUPPL","sponsor":"INDIVIOR","applicationNumber":"NDA022410"},{"date":"20120810","type":"SUPPL","sponsor":"INDIVIOR","applicationNumber":"NDA022410"},{"date":"20100830","type":"ORIG","sponsor":"INDIVIOR","applicationNumber":"NDA022410"},{"date":"20130808","type":"SUPPL","sponsor":"INDIVIOR","applicationNumber":"NDA022410"},{"date":"20250519","type":"SUPPL","sponsor":"INDIVIOR","applicationNumber":"NDA022410"},{"date":"20221216","type":"SUPPL","sponsor":"INDIVIOR","applicationNumber":"NDA022410"},{"date":"20220617","type":"SUPPL","sponsor":"INDIVIOR","applicationNumber":"NDA022410"},{"date":"20191007","type":"SUPPL","sponsor":"INDIVIOR","applicationNumber":"NDA022410"},{"date":"20231215","type":"SUPPL","sponsor":"INDIVIOR","applicationNumber":"NDA022410"},{"date":"20211119","type":"SUPPL","sponsor":"INDIVIOR","applicationNumber":"NDA022410"},{"date":"20240320","type":"SUPPL","sponsor":"INDIVIOR","applicationNumber":"NDA022410"},{"date":"20170112","type":"SUPPL","sponsor":"INDIVIOR","applicationNumber":"NDA022410"},{"date":"20210304","type":"SUPPL","sponsor":"INDIVIOR","applicationNumber":"NDA022410"},{"date":"20191031","type":"SUPPL","sponsor":"INDIVIOR","applicationNumber":"NDA022410"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":262,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Suboxone","genericName":"Suboxone","companyName":"Indivior Inc.","companyId":"indivior-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":7,"withResults":2},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:33:52.607005+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}